, Tracking Stock Market Picks
Enter Symbol:

down 77.70 %

PROTALIX BIOTHERAPEU (PLX) rated Buy with price target $10 by WBB Securities

Posted on: Thursday,  Mar 17, 2011  9:25 AM ET by WBB Securities

WBB Securities rated Buy PROTALIX BIOTHERAPEU (AMEX: PLX) on 03/17/2011, when the stock price was $6.28. Since
then, PROTALIX BIOTHERAPEU has lost 77.71% as of 08/27/2015's recent price of $1.40.
If you would have followed this WBB Securities's recommendation on PLX, you would have lost 77.7% of your investment in 1624 days.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system. Using its ProCellEx system, the Company is developing a pipeline of recombinant therapeutic proteins based on its plant cell-based expression technology that target pharmaceutical markets and that rely upon known biological mechanisms of action. Its product development candidate, prGCD, is a plant cell expressed recombinant Glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. Its product pipeline includes, among other candidates, therapeutic protein candidates for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, an acetylcholinesterase enzyme-based therapy for biodefense and intoxication treatments and an additional undisclosed therapeutic protein.

Research from WBB Securities provides investment professionals with up-to-date, in-depth, accurate and insightful reporting of companies that specialize in biotechnology, medical devices and healthcare. Our goal is to provide independent, straight-forward and up-to-date research so you can make educated decisions about your investments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/17/2011 9:25 AM Buy
6.28 10.00
as of 12/30/2011
1 Week down  -1.40 %
1 Month down  -18.78 %
3 Months up  7.17 %
1 YTD down  -21.49 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy